Yong HY, McKay KA, Daley CGJ, Tremlett H. Drug exposure and the risk of multiple sclerosis: a systematic review. Pharmacoepidemiol Drug Saf 2018;27:febrero. [Ref.ID 102630]

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]

Wang M-T, Liou J-T, Lin CW, Tsai C-L, Wang Y-H, Hsu Y-J, Lai J-H. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease. A nested case-control study. JAMA Intern Med 2018;178:febrero. [Ref.ID 102529]

Campaigno EP, Kebir I, Montastruc JL, Rueter M, Maret D, Lapeyre-Mestre M, Sallerin B, Despas F. Drug-induced dental caries: a disproportionality analysis using data from VigiBase. Drug Saf 2017;40:1249-58. [Ref.ID 102146]

Anónimo. EMA panel recommends approval of GSK’s triple inhaler to treat COPD. DIA Daily 2017:2. [Ref.ID 102050]

Fralick M, Avorn J, Kesselheim AS. The price of crossing the border for medications. N Engl J Med 2017;377:311-3. [Ref.ID 101925]

Anónimo. FDA announces list of off-patent drugs with no competition. DIA Daily 2017:1. [Ref.ID 101658]

Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]

Velzel J, Vlemmix F, Opmeer BC, Molkenboer JFM, Verhoeven CJ, van Pampus MG, Papatsonis DNM, Bais JMJ, Vollebregt KC, van der Esch L, van der Post JAM, Mol BW, Kok M. Atosiban versus fenoterol as a uterine relaxant for external cephalic version: randomised controlled trial. BMJ 2017;356:i6773. [Ref.ID 101398]

Anónimo. Décongestionnants rhinopharyngés: fibrillations auriculaires. Prescrire 2017;37:24. [Ref.ID 101364]

Anónimo. Indacaterol for chronic obstructive pulmonary disease. Therapeutics Letter 2016:1-2. [Ref.ID 101043]

Fitzgerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Buse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M, CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;388:2128-41. [Ref.ID 100929]

Bleecker ER, Fitzgerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M, SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting ß2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016;388:2115-27. [Ref.ID 100928]

Bush A, Frey U. Safety of long-acting beta-agonists in children with asthma. N Engl J Med 2016;375:889-91. [Ref.ID 100734]

Stempel DA, Szefler SJ, Pedersen S, Zeiger RS, Yeakey AM, Lee LA, Liu AH, Mitchell H, Kral KM, Raphiou IH, Prillaman BA, Buaron KS, Kirby SY, Pascoe SJ, for the VESTRI Investigators. Safety of adding salmeterol to fluticasone propionate in children with asthma. N Engl J Med 2016;375:840-9. [Ref.ID 100729]

Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016;375:65-74. [Ref.ID 100614]

Anónimo. GSK partners with Google’s Life Sciences spinoff to develop bioelectronic medicines. DIA Daily 2016:1. [Ref.ID 100563]

Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]

Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NMH, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting ß2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016;388:31-44. [Ref.ID 100481]

Chung KF. Dupilumab: a potential new treatment for severe asthma. Lancet 2016;388:3-4. [Ref.ID 100479]